[go: up one dir, main page]

AR104448A2 - Una composición que comprende un pestivirus atenuado de dvb - Google Patents

Una composición que comprende un pestivirus atenuado de dvb

Info

Publication number
AR104448A2
AR104448A2 ARP160101219A ARP160101219A AR104448A2 AR 104448 A2 AR104448 A2 AR 104448A2 AR P160101219 A ARP160101219 A AR P160101219A AR P160101219 A ARP160101219 A AR P160101219A AR 104448 A2 AR104448 A2 AR 104448A2
Authority
AR
Argentina
Prior art keywords
npro
deletion
coding sequence
dvb
composition
Prior art date
Application number
ARP160101219A
Other languages
English (en)
Inventor
Von Freyburg Martina
Meyer Christiane
Ege Andreas
Meyers Gregor
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34967522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR104448(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of AR104448A2 publication Critical patent/AR104448A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/15Reoviridae, e.g. calf diarrhea virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24311Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24311Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24361Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una composición que comprende un pestivirus atenuado de DVB de tipo 2, cepa viral NY93, caracterizada porque comprende: a) una deleción del residuo histidina en la posición aminoacídica 349 de la glicoproteína Eʳⁿˢ, donde dicha deleción en la secuencia codificante de la glicoproteína Eʳⁿˢ conduce a la inactivación de la actividad de RNasa que reside en la glicoproteína Eʳⁿˢ; y b) otra deleción en la secuencia codificante de Nᵖʳᵒ, donde dicha deleción en la secuencia codificante de Nᵖʳᵒ conduce a una proteína Nᵖʳᵒ que está codificada solo por los aminoácidos MELF, y donde dicha mutación en la secuencia codificante para Nᵖʳᵒ conduce a la inactivación de dicha Nᵖʳᵒ; c) una solución.
ARP160101219A 2004-05-19 2016-04-28 Una composición que comprende un pestivirus atenuado de dvb AR104448A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004025452A DE102004025452A1 (de) 2004-05-19 2004-05-19 Vakzine enthaltend BVDV

Publications (1)

Publication Number Publication Date
AR104448A2 true AR104448A2 (es) 2017-07-19

Family

ID=34967522

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050102032A AR049176A1 (es) 2004-05-19 2005-05-18 Vacuna que comprende un pestivirus atenuado
ARP160101219A AR104448A2 (es) 2004-05-19 2016-04-28 Una composición que comprende un pestivirus atenuado de dvb

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050102032A AR049176A1 (es) 2004-05-19 2005-05-18 Vacuna que comprende un pestivirus atenuado

Country Status (26)

Country Link
EP (1) EP1751276B9 (es)
JP (2) JP5006782B2 (es)
KR (1) KR100908798B1 (es)
CN (2) CN1989240B (es)
AR (2) AR049176A1 (es)
AT (1) ATE420949T1 (es)
AU (1) AU2005243488B2 (es)
BR (1) BRPI0510396B1 (es)
CA (1) CA2561719C (es)
CY (4) CY1109036T1 (es)
DE (2) DE102004025452A1 (es)
DK (1) DK1751276T5 (es)
ES (1) ES2321210T3 (es)
FR (3) FR15C0043I2 (es)
HU (2) HUS1500031I1 (es)
LU (3) LU92747I2 (es)
ME (1) ME01119B (es)
MX (1) MXPA06013298A (es)
NL (3) NL300745I1 (es)
NZ (1) NZ552088A (es)
PL (1) PL1751276T3 (es)
PT (1) PT1751276E (es)
RS (1) RS50753B9 (es)
SI (1) SI1751276T1 (es)
UY (1) UY28905A1 (es)
WO (1) WO2005111201A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179473B2 (en) 1998-06-05 2007-02-20 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
US7135561B2 (en) 2001-09-06 2006-11-14 Boehringer Ingelheim Vetmedica Gmbh Infectious bovine viral diarrhea virus clone
UY29915A1 (es) * 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
AR062917A1 (es) 2006-09-22 2008-12-17 Intervet Int Bv Nuevo mutante de pestivirus para uso en una vacuna.
CL2008003202A1 (es) 2007-10-29 2009-11-27 Boehringer Ingelheim Vetmedica Inc Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.
UY31930A (es) * 2008-06-25 2010-01-29 Boheringer Ingelheim Pharma Kg Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante
WO2010051210A1 (en) 2008-10-31 2010-05-06 Boehringer Ingelheim Vetmedica, Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
US8846054B2 (en) 2009-01-09 2014-09-30 Boehringer Ingelheim Vetmedica, Inc. Method of treating pregnant cows and/or heifers
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
ES2606605T3 (es) * 2010-09-21 2017-03-24 Intervet International B.V. Vacuna para el BVDV
JP6589159B2 (ja) * 2014-04-01 2019-10-16 共立製薬株式会社 新規ネコモルビリウイルス株、不活化ワクチン製剤、並びにネコモルビリウイルス感染症予防方法
US9993544B2 (en) * 2014-05-23 2018-06-12 Boehringer Ingelheim Vetmedica Gmbh Recombinant classical swine fever virus (CSFV) comprising substitution in the TAV epitope of the E2 protein
CN105779499B (zh) * 2016-03-23 2019-11-19 江苏科技大学 重组杆状病毒和其应用及构建该重组杆状病毒的载体
CN107823639B (zh) * 2017-11-10 2020-10-02 齐鲁动物保健品有限公司 牛病毒性腹泻病毒灭活疫苗及其制备方法
CN108707190B (zh) * 2018-04-18 2021-07-13 中国科学院武汉病毒研究所 猪瘟病毒ns5b蛋白保真度突变体及其应用
CN114853912B (zh) * 2022-05-24 2023-06-13 中国农业科学院兰州兽医研究所 一种牛病毒性腹泻病毒e2-e0融合蛋白、制备方法及应用
CN115960847B (zh) * 2023-01-11 2024-06-14 青岛大学 小分子依赖的内含肽自剪接系统在制备减毒活疫苗中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168942B1 (en) * 1998-11-10 2001-01-02 Pfizer Inc. Attenuated forms of bovine viral diarrhea virus
EP1104676A1 (en) * 1999-11-30 2001-06-06 Boehringer Ingelheim Vetmedica Gmbh Safe attenuated bovine viral diarrhea viruses for use in pregnant cows
CA2363493C (en) * 2000-11-22 2006-06-06 Xuemei Cao Attenuated forms of bovine viral diarrhea virus
DE10143813A1 (de) * 2001-09-06 2003-04-10 Boehringer Ingelheim Vetmed Infektiöser Rindervirusdiarrhoe-Virusklon

Also Published As

Publication number Publication date
RS50753B9 (sr) 2020-08-31
CA2561719C (en) 2015-01-27
UY28905A1 (es) 2005-12-30
JP5562316B2 (ja) 2014-07-30
FR15C0042I1 (fr) 2015-07-24
EP1751276B9 (en) 2020-05-27
DE102004025452A1 (de) 2006-01-19
NL300745I2 (es) 2016-01-26
CY2015021I1 (el) 2020-05-29
CA2561719A1 (en) 2005-11-24
LU92749I2 (fr) 2015-11-02
CY2015022I2 (el) 2024-02-16
EP1751276B1 (en) 2009-01-14
HUS1500031I1 (hu) 2019-11-28
HUS1500033I1 (hu) 2015-07-28
NL300745I1 (es) 2016-01-26
NL300743I2 (es) 2016-01-26
CY2015023I2 (el) 2024-02-16
JP5006782B2 (ja) 2012-08-22
DK1751276T5 (da) 2020-07-20
CY2015022I1 (el) 2020-05-29
CY2015021I2 (el) 2023-11-15
CY2015023I1 (el) 2020-05-29
CY1109036T1 (el) 2014-07-02
CN103352030A (zh) 2013-10-16
ES2321210T9 (es) 2020-11-04
JP2012061001A (ja) 2012-03-29
ES2321210T3 (es) 2009-06-03
AR049176A1 (es) 2006-07-05
NL300744I2 (es) 2016-01-26
NZ552088A (en) 2009-10-30
FR15C0044I1 (fr) 2015-07-24
AU2005243488B2 (en) 2011-07-07
MXPA06013298A (es) 2007-05-07
KR20070012862A (ko) 2007-01-29
NL300743I1 (es) 2016-01-26
LU92747I2 (fr) 2015-11-02
AU2005243488A1 (en) 2005-11-24
LU92748I2 (fr) 2015-11-02
BRPI0510396B1 (pt) 2020-08-18
DK1751276T3 (da) 2009-05-18
BRPI0510396A (pt) 2007-11-13
FR15C0043I2 (fr) 2016-05-27
ATE420949T1 (de) 2009-01-15
ME01119B (me) 2013-03-20
EP1751276A1 (en) 2007-02-14
NL300744I1 (es) 2016-01-26
DE602005012381D1 (de) 2009-03-05
CN1989240A (zh) 2007-06-27
PT1751276E (pt) 2009-02-24
JP2007537740A (ja) 2007-12-27
SI1751276T1 (sl) 2009-06-30
FR15C0042I2 (fr) 2018-11-16
CN103352030B (zh) 2018-08-10
KR100908798B1 (ko) 2009-07-22
PL1751276T3 (pl) 2009-06-30
RS50753B (sr) 2010-08-31
WO2005111201A1 (en) 2005-11-24
FR15C0043I1 (fr) 2015-07-24
CN1989240B (zh) 2013-07-31
FR15C0044I2 (fr) 2016-05-27

Similar Documents

Publication Publication Date Title
AR104448A2 (es) Una composición que comprende un pestivirus atenuado de dvb
AR079941A2 (es) Organismos clostridium atenuados recombinados y vacuna
AR029851A1 (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
AR044736A1 (es) Metodo para aumentar la resistencia de una planta frente a por lo menos un patogeno de plantas
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
AR049014A1 (es) Mimeticuerpos de glp-1 humanos , composiciones y usos
AR057213A1 (es) Acidos nucleicos que codifican secuencias tgev y prrsv para la expresion mejorada de secuencias prrsv
CO5700785A2 (es) Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal
BR9905902A (pt) Clone de cdna infeccioso do vìrus da sìndrome reprodutiva e respiratória de porcino norte-americana (prrs) e seus usos
MY151062A (en) Pseudoinfectious flavivirus and uses thereof
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
SG10201901482XA (en) Oncolytic adenovirus encoding a b7 protein
CL2008003794A1 (es) Virus de la estomatitis vesicular geneticamente modificado (vsv) que comprende por lo menos una mutacion de aminoacido en una region de alguna de las proteinas m, g y l del virus; metodo para producirlo; composicion inmunogenica que lo comprende; metodo para adaptar un virus en un cultivo celular.
CO6210761A2 (es) Vectores de virus oncoliticos de viruela
ES2532985T3 (es) Proteínas quiméricas de toxoide de Shiga
ES2124532T3 (es) Sistema vector-huesped utilizable en terapia genica.
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
ECSP034439A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
ATE552344T1 (de) Viren mit erhöhter lytischer kraft
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
MXPA05005202A (es) Vacuna.
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
AR015255A1 (es) Un fragmento de adn que conduce naturalmente la expresion de un gen vegetal que codifica para hexosa oxidasa o una porcion o una variante del fragmento deadn; una secuencia de adn quimerico que comprende el fragmento de adn; celulas vegetales, plantas y partes de plantas que comprenden la secuencia

Legal Events

Date Code Title Description
FC Refusal